EGFR and neoplasm: Tumor specific EGFR downstream signaling mutations in KRAS, [8, 31] BRAF, [31, 32] PTEN, [33] and PIK3CA [31, 34] cause reduced benefit of cetuximab therapy in colon carcinoma patients.